XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 154 filers reported holding XENON PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 1.16 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $154,164,251 | -15.9% | 4,513,005 | -5.2% | 2.00% | -13.4% |
Q2 2023 | $183,292,841 | +10.0% | 4,760,853 | +2.3% | 2.31% | -1.0% |
Q1 2023 | $166,599,766 | -9.8% | 4,654,925 | -0.6% | 2.34% | -15.0% |
Q4 2022 | $184,603,256 | +13.5% | 4,681,797 | +3.9% | 2.75% | +11.8% |
Q3 2022 | $162,595,000 | +21.7% | 4,504,020 | +2.6% | 2.46% | +13.8% |
Q2 2022 | $133,575,000 | +32.4% | 4,391,038 | +33.0% | 2.16% | +74.7% |
Q1 2022 | $100,894,000 | +3.4% | 3,300,427 | +5.7% | 1.24% | +24.4% |
Q4 2021 | $97,570,000 | +322.5% | 3,123,229 | +106.6% | 1.00% | +263.5% |
Q3 2021 | $23,096,000 | +31.2% | 1,511,543 | +59.9% | 0.27% | +17.6% |
Q2 2021 | $17,598,000 | +27.4% | 945,135 | +22.5% | 0.23% | +14.2% |
Q1 2021 | $13,808,000 | +101.5% | 771,410 | +73.2% | 0.20% | +83.8% |
Q4 2020 | $6,851,000 | +37.1% | 445,444 | -1.3% | 0.11% | +7.8% |
Q3 2020 | $4,996,000 | -14.2% | 451,307 | -2.8% | 0.10% | -27.5% |
Q2 2020 | $5,821,000 | +11.0% | 464,233 | +0.4% | 0.14% | -18.9% |
Q1 2020 | $5,243,000 | – | 462,332 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |